PART I . Overview We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation ofour novel Drug Response Predictor (DRP) platform. TheDRP technology is designed to define the gene expression signatures in cancer cells that predict the cancer cells sensitivity to a specific cancer therapeutic. Once defined, the DRP gene expression signature can then be assessed i...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001437749-26-010310 | EDGAR | 94K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010198 | EDGAR | — |
| 2024-03-08 | 2023-12-31 | 0001213900-24-020864 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0001213900-23-019295 | EDGAR | — |
| 2022-05-17 | 2021-12-31 | 0001213900-22-027311 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001437749-25-035003 | EDGAR | 18K words |
| 2025-08-15 | 2025-06-30 | 0001437749-25-027146 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001437749-25-015780 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001437749-24-035314 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001213900-24-065252 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042997 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086382 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001213900-23-066893 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001213900-23-038609 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072355 | EDGAR | — |
| 2022-10-07 | 2022-06-30 | 0001213900-22-062840 | EDGAR | — |
| 2022-05-27 | 2022-03-31 | 0001213900-22-030179 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001213900-26-038061 | EDGAR | 4K words |
| 2026-03-09 | 0001213900-26-024952 | EDGAR | — |
| 2026-03-06 | 0001213900-26-024339 | EDGAR | — |
| 2026-02-19 | 0001213900-26-018161 | EDGAR | — |
| 2026-02-04 | 0001213900-26-011826 | EDGAR | — |
| 2026-01-29 | 0001213900-26-009157 | EDGAR | — |
| 2025-12-23 | 0001213900-25-124935 | EDGAR | — |
| 2025-12-08 | 0001213900-25-118989 | EDGAR | — |
| 2025-09-24 | 0001213900-25-090872 | EDGAR | — |
| 2025-09-22 | 0001213900-25-090197 | EDGAR | — |
211 total filings indexed. 184 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001860657 |
| Ticker | ALLR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.allarity.com |
| Listed | 2021-12-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report